 Home > Active Ingredient News > Antitumor Therapy > BJU Int: a population-based randomized trial of clinically significant prostate cancer screening

BJU Int: a population-based randomized trial of clinically significant prostate cancer screening

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

time lapse imaging

cancer diagnosis letter

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

General principles of cancer screening include the detection of clinically significant disease in an asymptomatic population with known natural progression, and early diagnosis and treatment that are effective in improving outcomes and reducing mortality

Recently, researchers from Finland published an article in BJU Int evaluating the feasibility of a population-based screening test using prostate-specific antigen (PSA), kallikrein panel and multiparametric magnetic resonance imaging (MRI).

Evaluated the feasibility of a population-based screening test using prostate-specific antigen (PSA), kallikrein panel, and multiparametric magnetic resonance imaging (MRI) and aimed to minimize overdiagnosis while preserving mortality benefits Evaluated the feasibility of a population-based screening test using prostate-specific antigen (PSA), kallikrein panel, and multiparametric magnetic resonance imaging (MRI) and aimed to minimize overdiagnosis while preserving mortality benefits

The researchers evaluated the feasibility of the screening algorithm in terms of engagement, screening test results, and cancer detection

Of the 399 men invited, 158 (40%) participated in the trial, of whom 27 had PSA levels ≥3 ng/mL (7% of invitees, 17% of participants)

Thus, additional testing (kallikrein panel and MRI) after PSA reduced biopsy rates by 56%

Outcomes of men with cancer screened in the study

Taken together, their results demonstrate that their screening protocol is effective, substantially reducing the proportion of biopsies

Their results demonstrate that their screening protocol is effective, resulting in a substantial reduction in the proportion of biopsies

Original source:

Antti Rannikko, Mare Leht, Tuomas Mirtti et al.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.